Nasdaq-listed Sonnet BioTherapeutics, Inc. has agreed to merge with Rorschach I LLC to form Hyperliquid Strategies, Inc., which will initiate a HYPE reserve strategy. Upon completion of the transaction, the new entity is expected to hold 12.60 million HYPE tokens and $305 million in cash for a total valuation of $888 million.
纳斯达克上市公司 Sonnet BioTherapeutics, Inc. 已同意与 Rorschach I LLC 合并成为 Hyperliquid Strategies, Inc.,该公司将启动HYPE储备策略,交易完成后新实体预计将持有 1260 万个 HYPE 代币和 3.05 亿美元现金,总估值为 8.88 亿美元。